Hepatitis C virus enters human peripheral neuroblastoma cells - Evidence for extra-hepatic cells sustaining hepatitis C virus penetration

Journal of Viral Hepatitis

Volumn 18, Issue 8, 2011, Pages 562-570

  Burgel B ^a   Friesland, M ^a   Koch, A ^b   Manns, M P ^c   Wedemeyer, H ^c   Weissenborn, K ^c   Schulz Schaeffer, W J ^d   Pietschmann, T ^a   Steinmann, E ^a   Ciesek, S ^a,c  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

extrahepatic reservoir; HCV; hepatitis C Virus; neuroblastoma; SKNMC

Indexed keywords

LUCIFERASE; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CHILD; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; FEMALE; GENOTYPE; GLIOBLASTOMA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INCIDENCE; INOCULATION; MALE; MICROGLIA; NEUROBLASTOMA CELL; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RNA REPLICATION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENES, REPORTER; GENETIC VECTORS; HEPACIVIRUS; HUMANS; LUCIFERASES; MEMBRANE PROTEINS; RNA, VIRAL; SCAVENGER RECEPTORS, CLASS B; TRANSFECTION; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 79960672334     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01339.x     Document Type: Article

References (31)

1. Seeff LB, Hoofnagle JH,. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36 (5 Suppl 1): S1-S2. (Pubitemid 35253458)
2. Kenny-Walsh E,. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340 (16): 1228-1233. (Pubitemid 29181642)
3. Foster GR,. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999; 31 (Suppl 1): 250-254. (Pubitemid 30002728)
4. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM,. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol 1999; 94 (5): 1355-1360. (Pubitemid 29214653)
5. Weissenborn K, Tryc AB, Heeren M, et al. Hepatitis C virus infection and the brain. Metab Brain Dis 2009; 24 (1): 197-210.
6. Singh N, Gayowski T, Wagener MM, Marino IR,. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999; 67 (1): 69-72. (Pubitemid 29061139)
7. Buskila D,. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin North Am 2009; 35 (1): 111-123.
8. Zignego AL, Giannini C, Monti M, Gragnani L,. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007; 1: S38-S45. (Pubitemid 47528193)
9. Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A,. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2003; 101 (1): 52-57. (Pubitemid 36025886)
10. Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196 (3): 361-370. (Pubitemid 47093886)
11. Wilkinson J, Radkowski M, Laskus T,. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 2009; 83 (3): 1312-1319.
12. Fishman SL, Murray JM, Eng FJ, Walewski JL, Morgello S, Branch AD,. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 2008; 197 (4): 597-607. (Pubitemid 351321539)
13. Murray J, Fishman SL, Ryan E, et al. Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol 2008; 14 (1): 17-27. (Pubitemid 351314970)
14. Schaller T, Appel N, Koutsoudakis G, et al. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol 2007; 81 (9): 4591-4603. (Pubitemid 46668657)
15. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309 (5734): 623-626. (Pubitemid 41033648)
16. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102 (26): 9294-9299. (Pubitemid 40923557)
17. Bartosch B, Dubuisson J, Cosset FL,. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197 (5): 633-642. (Pubitemid 36314658)
18. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100 (12): 7271-7276. (Pubitemid 36706428)
19. Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21 (19): 5017-5025.
20. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282 (5390): 938-941. (Pubitemid 28507525)
21. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446 (7137): 801-805. (Pubitemid 46582027)
22. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457 (7231): 882-886.
23. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T,. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009; 83 (4): 2011-2014.
24. Koutsoudakis G, Kaul A, Steinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80 (11): 5308-5320.
25. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103 (19): 7408-7413. (Pubitemid 43727846)
26. Berberich-Siebelt F, Klein-Hessling S, Hepping N, et al. C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells. Eur J Immunol 2000; 30 (9): 2576-2585.
27. Kalajzic I, Stover ML, Liu P, Kalajzic Z, Rowe DW, Lichtler AC,. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology 2001; 284 (1): 37-45. (Pubitemid 32476694)
28. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23 (4): 628-633.
29. Casado-Zapico S, Rodriguez-Blanco J, Garcia-Santos G, et al. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 2010; 48 (1): 72-80.
30. Puchner KP, Berg T,. [Extrahepatic manifestations of chronic hepatitis C virus infection]. Z Gastroenterol 2009; 47 (5): 446-456.
31. Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 2005; 102 (51): 18544-18549. (Pubitemid 43011262)